Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study
| Autor: | Roger Trinh, Thomas Podsadecki, Joseph Gathe, Ruth Soto-Malave, Michael Norton, Jacques Reynes, Min Tian, Linda M Fredrick, Roula B Qaqish, Angela Nilius, Federico Pulido |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Immunology Urology Lopinavir/ritonavir HIV Infections Pilot Projects Pharmacology Emtricitabine Plasma Antiretroviral Therapy Highly Active Virology medicine Humans business.industry Lopinavir Middle Aged Viral Load Raltegravir CD4 Lymphocyte Count Regimen Treatment Outcome Infectious Diseases Anti-Retroviral Agents Tolerability HIV-1 RNA Viral Female Ritonavir business Viral load medicine.drug |
| Zdroj: | AIDS Research and Human Retroviruses. 29:256-265 |
| ISSN: | 1931-8405 0889-2229 |
| DOI: | 10.1089/aid.2011.0275 |
| Popis: | Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study comparing a regimen of lopinavir/ritonavir (LPV/r) 400/100 mg twice daily in combination with either raltegravir (RAL) 400 mg twice daily or tenofovir/emtricitabine (TDF/FTC) 300/200 mg once daily in ARV-naive adults. A total of 206 subjects were randomized and treated (LPV/r+RAL, N=101; LPV/r+TDF/FTC, N=105). Demographics and baseline characteristics were similar across treatment groups. At 96 weeks, 66.3% of subjects receiving LPV/r+RAL and 68.6% of subjects receiving LPV/r+TDF/FTC were responders (plasma HIV-1 RNA levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|